Drug Trial Radar · NCT05561634
Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
82
Planned (sponsor's estimate)
Start
Jun 20, 2023
Primary completion
Jun 20, 2029
Study completion Jun 20, 2029
Sponsor
- Lead sponsor
- University Hospital, LilleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sun Pharmaceutical Industries Limited
- First posted
- Sep 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Locally advanced basal cell carcinoma (BCC) are large BCCs or BCCs located in areas subject to functional and aesthetic risk following surgery or radiotherapy. In these particular situations, surgery and radiotherapy are sometimes not appropriate, and Sonic Hedgehog inhibitors (SHHi) (Vismodegib and Sonidegib) can be proposed. SHHi are effective treatments in laBCC but most CR patients discontinue treatment because of tolerability. Approximately 65% of the population experience a relapse after discontinuation. A few cases of patients treated concomitantly by radiotherapy and vismodegib have been reported in the literature, suggesting that combining vismodegib and concomitant radiotherapy results in an improved overall response compared to a single modality treatment. There is no study evaluating a "consolidation radiotherapy" after complete response to SHHi. We carry out a prospective multicenter study in order to evaluate consolidation radiotherapy in patients with laBCC after achieving complete response with SHHi, with the hypothesis of reducing recurrence after discontinuation of SHHi.
Conditions
- Basal Cell Carcinoma
- Radiotherapy; Complications
Interventions
RadiotherapyRadiation
Irradiation of the tumoral bed.
ObservationOther
Patients will be followed up in consultation every 3 months.
VismodegibDrug
Sonic Hedgehog inhibitors (SHHi) = Vismodegib et Sonidegib,
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of a local relapse at 2 years in both groups.Time frame: At 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU Lille
Lille, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.